None listed
Conditions
Interventions
None listed
Sponsors
Gachon University Gil Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. severe obesity and comorbidities scheduled for bariatric surgery: body mass index = 30 kg/m2 with comorbidities (fasting glycemia or glycosylated hemoglobin > 5.7%, diabetes, fatty liver disease, hypertension, triglyceridemia, or metabolic syndrome with at least one of the following) or body mass index = 35 kg/m2 2. Age: 19 years of age or older, but not older than 75 years of age 3. determined to be eligible for the study based on the following laboratory tests at screening: physical examination, serology, hematology, blood chemistry, and urinalysis 4. No congenital or treatment-requiring chronic diseases and no pathological symptoms or findings as a result of internal medicine examination. 5. have received a detailed explanation of this study and are able to fully understand it, and have voluntarily decided to participate as a subject and have given written consent to comply with the precautions.
Exclusion criteria
Exclusion criteria: 1. age: less than 19 years old, 76 years old or older 2. reoperated patients including gastric band surgery 3. unable to tolerate the noise or isolation environment in the MRI examination room, or who are contraindicated for MRI examination (e.g., people with iron implants or devices in the body, pacemakers, vascular clips, people with artificial eyes or ears, or other foreign bodies in the body that may be affected by magnetic fields) 4. average daily alcohol consumption exceeding 30 grams (approximately 3 glasses of soju) for men and 20 grams (approximately 2 glasses of soju) for women in the past 5 years and lasting for more than 3 months (approximately 3 or more bottles of soju for men and 2 or more bottles of soju for women per week) 5. substance abusers (narcotics) 6. history of taking drugs that cause secondary fatty liver within the past year (corticosteroids, tamoxifen, amiodaronemethotrexate, etc.) 7. other identified liver diseases: hepatitis B or C, autoimmune hepatitis, drug-induced liver injury, other liver diseases (e.g., anti-trypsin deficiency, primary biliary cirrhosis, primary sclerosing cholangitis, etc.) and biliary tract disease 8. pregnant women 9. any other systemic disease deemed unsuitable for participation in this study 10. those who are judged to be unsuitable for participation in the study according to the judgment of the principal investigator and the person in charge of the study (physician in charge)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Metabolomics analysis of pre- and post-operative blood and urine to identify metabolomic changes associated with weight loss before and after bariatric surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Metabolomics analysis of pre- and post-operative blood and urine to identify metabolomic changes associated with weight regain after bariatric surgery;Metabolomics analysis of pre- and post-operative blood and urine to identify metabolomic changes associated with type 2 diabetes after bariatric surgery;Evaluate the degree of improvement in NAFLD with pre- and post-operative weight loss by correlating the extent of fibrosis on histology with liver stiffness measurement (LSM, in kPa) on MRE examination;Analysis of gastric, liver, and adipose tissues collected during bariatric surgery to identify transcriptomic changes related to altered metabolites. | — |
Countries
Korea, Republic of
Contacts
Public ContactJi-Hyeon Park
Gachon University Gil Medical Center
Outcome results
None listed